Multidisciplinary team meetings with dermatologists, rheumatologists, and other healthcare professionals can be helpful to direct the best care for patients with difficult-to-treat psoriatic arthritis.
ATLANTA New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that combining a nonsteroidal anti-inflammatory drug and TNF inhibitor did not significantly slow radiographic spinal progression in radiographic axial spondyloarthritis patients ( Abstract #0546 )
There was a strong, but not statistically significant, signal of reduced spinal structural damage with the combination of a selective COX-2 inhibitor and a TNF inhibitor in axial spondyloarthritis.
Data after 24 weeks of treatment with bimekizumab in patients with axial spondyloarthritis show good responses overall regardless of prior experience with a tumor necrosis factor inhibitor.